Clinical Trials · NCT06953882
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Yale University
- Enrollment
- 140
- Start date
- Jul 2025
- Locations
- 1 site, United States
- Primary endpoint
- Discontinuation rate of ribociclib in patients with resected moderate to high-anatomical risk, low-genomic risk, ER-positive, HER2-negative breast cancer